Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Instant immunity through chemically programmable vaccination and covalent self-assembly

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.

2 Mar 2009

Novel approach to gene hunting uncovers possible new targets for Crohn's disease drugs

Discovering the different genes that contribute to a complex disease is like searching in the proverbial haystack for an unknown number of needles--some much smaller than others, often blending into the background, and many of them widely separated from each other.

26 Feb 2009

Implicit licenses clinical stage antibody program from Lilly

Implicit Bioscience Ltd has announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

25 Feb 2009

Scientists identify lab-made proteins that neutralize a broad range of influenza A viruses

Scientists have identified a small family of lab-made proteins that neutralize a broad range of influenza A viruses, including the H5N1 avian virus, the 1918 pandemic influenza virus and seasonal H1N1 flu viruses.

23 Feb 2009

Nanoparticles detect dying cancer cells

Two years ago, researchers at the University of South Australia discovered a new molecular marker specific for chemotherapy-induced cancer cell death. Now, those same investigators have used this marker to develop an imaging agent that can pinpoint tumor cell death using magnetic resonance imaging.

23 Feb 2009

Scientists identify lab-made proteins that neutralize multiple strains of seasonal and pandemic flu

22 Feb 2009

Scientists identify human monoclonal antibodies effective against bird flu

Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.

22 Feb 2009

Study on ustekinumab for treatment of psoriatic arthritis published

A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis (PsA).

11 Feb 2009

More children need medical help for respiratory syncytial virus than previously known

More than 2 million children with Respiratory Syncytial Virus (RSV) are seen in hospitals, emergency rooms and doctors' offices in the United States every year -- many more than doctors know.

5 Feb 2009

BioGenes as new designated partner in EU funded dementia project

BioGenes GmbH, a specialist in sophisticated antibody development, has been chosen as a new partner of cNEUPRO. cNEUPRO is a EU funded research project to analyse neurodegenerative diseases and discover novel biomarkers, and so improve early and differential diagnosis of Alzheimer's dementia.

2 Feb 2009

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin ávâ6, including compositions related to its lead product, STX-100.

23 Jan 2009

Pre-emptive treatment helped curtail skin toxicity with Panitumumab

With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

19 Jan 2009

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

8 Jan 2009

FDA issues complete response to biologics license application for ustekinumab

Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab.

21 Dec 2008

Still wide racial disparities in colorectal cancer rates

An American Cancer Society reports says despite unprecedented progress in reducing incidence and death rates from colorectal cancer, the gap between blacks and whites continues to grow.

15 Dec 2008

Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2008